Track topics on Twitter Track topics that are important to you
On August 9, 2017, the National Institute for Health and Care Excellence (NICE) published technology appraisal guidance1 recommending cabozantinib, within its marketing authorisation, as an option for the treatment of advanced renal cell carcinoma in adults after VEGF-targeting therapy, only if the company provides cabozantinib with the discount agreed.NEXT ARTICLE
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...
Renal Cell Carcinoma
Renal cell cancer (renal adenocarcinoma or hypernephroma) is the most common type of kidney cancer in adults. More than 8 in every 10 (80%) kidney cancers diagnosed in the UK are this type. In renal cell cancer the cancerous cells start in the lini...